Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1678-1684

  Dittrick, George W ^a   Weber, Jill M ^a   Shridhar, Ravi ^a   Hoffe, Sarah ^a   Melis, Marcovalerio ^b   Almhanna, Khaldoun ^a   Barthel, James ^a   McLoughlin, James ^c   Karl, Richard C ^a   Meredith, Kenneth L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b New York Presbyterian Veterans Administration   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTINUOUS INFUSION; DATA BASE; DISEASE FREE SURVIVAL; EARLY CANCER; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84862528460     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2078-4     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67(6):381-90. (Pubitemid 10059625)
3. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990; 77(8):845-57. (Pubitemid 20249685)
4. Wu PC, Posner MC, Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8): 481-8. (Pubitemid 37009956)
5. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):707-16. (Pubitemid 46684100)
6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [see comment]. N Engl J Med. 2006;355(1):11-20.
7. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamouscell cancer of the esophagus. N Engl J Med. 1997;337(3):161-7. (Pubitemid 27306287)
8. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [see comment]. Lancet Oncol. 2005;6(9):659-68. (Pubitemid 41222756)
9. Gebski V, Burmeister B, Smithers BM, et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [see comment]. Lancet Oncol. 8(3): 226-34. (Pubitemid 46291702)
10. Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60(2):427-36. (Pubitemid 39233461)
11. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer [see comment]. N Engl J Med. 1998;339(27):1979-84. (Pubitemid 29024130)
12. Naughton P, Walsh TN, Naughton P, Walsh TN. Preoperative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer. Cancer Treat Rev. 2004;30(1): 141-4.
13. Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):1930-6; discussion 1936-7.
14. Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15(2):121-4. (Pubitemid 35264633)
15. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104(11):2365-72. (Pubitemid 41691557)
16. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma [see comment]. J Clin Oncol. 2001;19(2):305-13. (Pubitemid 32112841)
17. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comment] [erratum appears in N Engl J Med 1999;341(5):384]. N Engl J Med. 1996;335(7):462-7. (Pubitemid 26269945)
18. Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010; 17(4):1159-67.
19. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7): 1347-55. (Pubitemid 40410728)
20. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11): 2680-6. (Pubitemid 24166250)
21. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival [see comment]. J Clin Oncol. 2003;21(21):4009-15. (Pubitemid 46606216)
22. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64(3):765-9. (Pubitemid 27435689)
23. McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg. 2008;206(5): 879-86; discussion 886-7.
24. Aguirre ACR, Ramos-Font C, Portero RV, Cook GJR, Elvira JML, Tabares AR. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer systematic review of the literature. Ann Surg. 2009;250(2):247-54.
25. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009;249(5):764-7.
26. Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6): 902-8.
27. Schauer M, Janssen KP, Rimkus C, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010;16(1):330-7.
28. Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009;250(5):729-37.